To find the fibrillation threshold under rapidly changing conditions a method of its determination with long-lasting stimuli (100--300 msec) far exceeding the period of the highest vulnerability is described. The figures of the fibrillation threshold found by way of stimulating the heart with short and long impulses were partically identical. Intravenous administration of 4 mg/kg Lidocaine resulted in an increase of the fibrillation threshold in the experimental dogs, without changing the projection of the stimulus producing the fibrillation onto the force-interval curve and at the same time increasing the excitability of the myocardium. Intravenous 1 mg/kg Propranolol elevated the fibrillation threshold causing a parallel rightward shift in the projection of the stimulus on the force-interval curve and decreasing the exitability of the heart.
Download full-text PDF |
Source |
---|
JACC Clin Electrophysiol
January 2025
Division of Cardiac Electrophysiology, Virginia Commonwealth University, Richmond, Virginia, USA; Division of Cardiac Electrophysiology, Central Virginia Veterans Affairs Health System, Richmond, Virginia, USA. Electronic address:
Circulation
January 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (Y.N.V.R., A.T., M.M.R., B.A.B.).
Background: Plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) is commonly used to diagnose heart failure with preserved ejection fraction (HFpEF), but its diagnostic performance in the ambulatory/outpatient setting is unknown because previous studies lacked objective reference standards.
Methods: Among patients with chronic dyspnea, diagnosis of HFpEF or noncardiac dyspnea was determined conclusively by exercise catheterization in a derivation cohort (n=414), multicenter validation cohort 1 (n=560), validation cohort 2 (n=207), and a nonobese Japanese validation cohort 3 (n=77). Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation.
Brain Commun
January 2025
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health (AgeCap) at the University of Gothenburg, Mölndal 43139, Sweden.
Atrial fibrillation and heart failure have both been suggested to increase stroke and dementia risk. However, in observational studies, reversed causation and unmeasured confounding may occur. To mitigate these issues, this study aims to investigate if higher genetic risk for atrial fibrillation and heart failure increases dementia and stroke risk.
View Article and Find Full Text PDFThromb Haemost
January 2025
St Joseph's Hospital, Hamilton, Canada.
A DOAC concentration threshold above which an impact on surgical hemostasis starts to occur is unknown. Thrombin generation assays (TGAs) provide a measure of the coagulation phenotype. This study aimed to determine whether preoperative TGA parameters are associated with postoperative bleeding, and whether this is partly due to residual DOAC levels.
View Article and Find Full Text PDFJ Cardiovasc Electrophysiol
January 2025
Division of Cardiology, Boston University Medical Center, Boston, Massachusetts, USA.
Background: Catheter ablation improves symptoms and quality of life in atrial fibrillation patients, but its effect on adverse cardiovascular outcomes and mortality remains uncertain. Bayesian analysis of randomized controlled trials offers a deeper understanding of treatment effects beyond conventional p-value thresholds.
Methods: We conducted a post hoc Bayesian reanalysis of CABANA and four similar trials to estimate catheter ablation's effect on cardiovascular and survival outcomes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!